Pfizer (NYSE:PFE) PT Set at $40.00 by UBS

Google+ Pinterest LinkedIn Tumblr +

UBS set a $40.00 worth goal on Pfizer (NYSE:PFE) in a analysis report report printed on Wednesday, December sixth, www.boersen-zeitung.de experiences. The agency at the moment has a purchase score on the biopharmaceutical firm’s inventory.

Various different equities analysis analysts have additionally not too long ago commented on PFE. Cowen set a $43.00 worth goal on Pfizer and gave the corporate a purchase score in a report on Monday, August 14th. Berenberg Financial institution reissued a maintain score and set a $36.00 worth goal (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Jefferies Group reissued a maintain score and set a $35.00 worth goal on shares of Pfizer in a report on Friday, August 18th. BMO Capital Markets reissued a purchase score and set a $37.00 worth goal on shares of Pfizer in a report on Wednesday, September sixth. Lastly, Vetr minimize Pfizer from a purchase score to a maintain score and set a $35.71 worth goal on the inventory. in a report on Wednesday, September 13th. Two analysts have rated the inventory with a promote score, six have given a maintain score and 13 have issued a purchase score to the corporate’s inventory. The inventory presently has a consensus score of Purchase and a median worth goal of $38.77.

Pfizer (NYSE:PFE) traded up $zero.74 throughout noon buying and selling on Wednesday, hitting $37.20. The inventory had a buying and selling quantity of 37,779,656 shares, in comparison with its common quantity of 14,408,752. Pfizer has a 12-month low of $30.90 and a 12-month excessive of $37.22. The corporate has a market cap of $217,387.00, a PE ratio of 14.59, a price-to-earnings-growth ratio of two.57 and a beta of 1.01. The corporate has a debt-to-equity ratio of zero.56, a present ratio of 1.43 and a fast ratio of 1.15.

Pfizer (NYSE:PFE) final introduced its earnings outcomes on Tuesday, October 31st. The biopharmaceutical firm reported $zero.67 EPS for the quarter, topping the Zacks’ consensus estimate of $zero.65 by $zero.02. Pfizer had a return on fairness of 25.41% and a web margin of 18.69%. The corporate had income of $13.17 billion for the quarter, in comparison with analysts’ expectations of $13.17 billion. Throughout the identical interval final yr, the agency earned $zero.61 EPS. Pfizer’s income for the quarter was up .9% in comparison with the identical quarter final yr. analysts count on that Pfizer will publish 2.59 EPS for the present fiscal yr.

The corporate additionally not too long ago disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of file on Friday, November 10th got a dividend of $zero.32 per share. The ex-dividend date was Thursday, November ninth. This represents a $1.28 dividend on an annualized foundation and a dividend yield of three.44%. Pfizer’s payout ratio is 79.01%.

In associated information, EVP Alexander R. Mackenzie offered 7,350 shares of Pfizer inventory in a transaction dated Monday, October 2nd. The inventory was offered at a median worth of $35.65, for a complete worth of $262,027.50. Following the completion of the transaction, the chief vp now owns 117,432 shares within the firm, valued at $four,186,450.80. The transaction was disclosed in a doc filed with the SEC, which is on the market at this hyperlink. Additionally, insider Alexander R. Mackenzie offered 14,700 shares of Pfizer inventory in a transaction dated Wednesday, November 1st. The inventory was offered at a median worth of $35.30, for a complete worth of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares of the corporate’s inventory, valued at roughly $four,145,349.60. The disclosure for this sale might be discovered here. Firm insiders personal zero.06% of the corporate’s inventory.

Various institutional traders and hedge funds have not too long ago added to or diminished their stakes in PFE. Shine Funding Advisory Providers Inc. purchased a brand new stake in Pfizer within the second quarter price about $102,00zero. Mckinley Capital Administration LLC Delaware purchased a brand new stake in Pfizer within the second quarter price about $103,00zero. D. Scott Neal Inc. lifted its stake in Pfizer by 19.three% within the second quarter. D. Scott Neal Inc. now owns three,112 shares of the biopharmaceutical firm’s inventory price $105,00zero after buying an extra 504 shares over the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a brand new stake in shares of Pfizer in the course of the first quarter valued at roughly $121,00zero. Lastly, Herndon Capital Administration LLC purchased a brand new stake in shares of Pfizer in the course of the second quarter valued at roughly $120,00zero. Institutional traders personal 69.89% of the corporate’s inventory.

ILLEGAL ACTIVITY NOTICE: This text was initially printed by The Ledger Gazette and is the property of of The Ledger Gazette. In case you are studying this text on one other website, it was illegally stolen and republished in violation of U.S. and worldwide trademark & copyright legislation. The authorized model of this text might be seen at https://ledgergazette.com/2017/12/16/pfizer-pfe-given-a-40-00-price-target-at-ubs.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based international biopharmaceutical firm. The Firm is engaged within the discovery, improvement and manufacture of healthcare merchandise. Its international portfolio contains medicines and vaccines, in addition to shopper healthcare merchandise. The Firm manages its business operations by means of two enterprise segments: Pfizer Progressive Well being (IH) and Pfizer Important Well being (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Obtain Information & Rankings for Pfizer Every day – Enter your e mail tackle beneath to obtain a concise every day abstract of the newest information and analysts’ scores for Pfizer and associated firms with MarketBeat.com’s FREE daily email newsletter.



Source link

Share.

Leave a Reply

%d bloggers like this: